The CYPHER™ Stent Study in Patients With Small de Novo Coronary Artery Lesions. (SVELTE)
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Multicenter, Nonrandomized, Historical Controlled Study In Patients With De Novo Coronary Artery Lesions In Small VessELs Treated With The CYPHER™ STEnt|
- In-lesion late lumen loss [ Time Frame: 8-moths post-procedure ] [ Designated as safety issue: Yes ]
|Study Start Date:||November 2002|
|Study Completion Date:||April 2006|
|Primary Completion Date:||November 2003 (Final data collection date for primary outcome measure)|
Cypher Sirolimus-Eluting Stent
PCI with Cypher Sirolimus-Eluting Stent
Other Name: drug-eluting stent
This is an international, multicenter (up to 10 sites), nonrandomized, historically controlled study in patients with De Novo coronary artery lesions in small vessels treated with the CYPHER™ (sirolimus-eluting) stent as compared to the small vessel tercile uncoated Bx VELOCITYTM Stent patients from the SIRIUS Trial. A total of up to 100 patients will be enrolled in this study.
Patients with de novo native coronary artery lesions >=15mm and <=30mm in length and >=2.25 mm to <=2.75 mm in diameter by visual estimation will be treated with the CYPHER™ (sirolimus-eluting) stent. Patients will be followed at 30 days, 6, 8, 9 months and at 1, 2 and 3 years post-procedure, with a repeat angiography at 8 months. In all patients Intravascular Ultrasound (IVUS) will be performed before (only in case of crossing success) and after the initial procedure. An IVUS control will also be done at 8 months follow up to assess neo-intimal growth and remodeling.
This is a single lesion treatment study. Patients may have other lesions treated before the treatment of the intended lesion in the small vessel (a non-target lesion may not be located in the target vessel!). Post-procedural treatment of another lesion is only allowed after the 30-day follow-up contact has been completed or in case this is clinically needed.
It is anticipated that the total length of the study will be 39 months: 3 months to complete patient enrollment and 3 years for follow-up.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00235066
|University Hospital, Swiss Cardiovascular CenterBern|
|Bern, Switzerland, 3010|
|Principal Investigator:||Bernhard Meier, MD||University of Bern|